Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the

Adenoviridae / genetics Apoptosis / drug effects Asbestos / toxicity Cell Cycle Proteins / antagonists & inhibitors Cell Line, Tumor Cell Survival / drug effects DNA Damage / drug effects Humans Mesothelioma, Malignant / chemically induced Oncolytic Virotherapy Oncolytic Viruses / genetics Phosphorylation / drug effects Protein Kinase Inhibitors Protein-Tyrosine Kinases / antagonists & inhibitors Pyrazoles / pharmacology Pyrimidinones / pharmacology
AZD1775 DNA damage response G2/M checkpoint MK-1775 WEE1 adavosertib apoptosis dl922-947 malignant mesothelioma oncolytic adenovirus

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Oct 2020
Historique:
received: 04 08 2020
revised: 29 09 2020
accepted: 30 09 2020
entrez: 6 10 2020
pubmed: 7 10 2020
medline: 13 3 2021
Statut: epublish

Résumé

Malignant mesothelioma (MM) is a very aggressive asbestos-related cancer, for which no therapy proves to be effective. We have recently shown that the oncolytic adenovirus

Identifiants

DOI: 10.3390/ijms21197333 PMID: 33020398 PMC: PMC7582744
pubmed: 33020398
pii: ijms21197333
doi: 10.3390/ijms21197333
pmc: PMC7582744
pii:
doi:

Substances chimiques

Cell Cycle Proteins 0
Protein Kinase Inhibitors 0
Pyrazoles 0
Pyrimidinones 0
Asbestos 1332-21-4
Protein-Tyrosine Kinases EC 2.7.10.1
WEE1 protein, human EC 2.7.10.2
adavosertib K2T6HJX3I3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet Respir Med. 2019 Feb;7(2):99
pubmed: 30660508
Cancer Res. 2020 Feb 1;80(3):510-523
pubmed: 31551363
J Hematol Oncol. 2014 Aug 01;7:53
pubmed: 25084614
Mol Cancer Ther. 2020 Feb;19(2):661-672
pubmed: 31694888
Cancer Cell Int. 2012 Nov 13;12(1):45
pubmed: 23148684
Endocr Relat Cancer. 2013 Aug 19;20(5):633-47
pubmed: 23839822
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
Front Oncol. 2017 Aug 24;7:179
pubmed: 28884088
Biochem Pharmacol. 2019 Aug;166:323-334
pubmed: 31176618
Front Immunol. 2018 Apr 26;9:866
pubmed: 29755464
Clin Cancer Res. 2018 Oct 15;24(20):5153-5164
pubmed: 29941481
Semin Cancer Biol. 2020 Apr;61:11-22
pubmed: 31546009
Ann Transl Med. 2017 Jun;5(11):238
pubmed: 28706906
Clin Cancer Res. 2020 Mar 15;26(6):1213-1219
pubmed: 31857431
Expert Opin Investig Drugs. 2018 Sep;27(9):741-751
pubmed: 30102076
Clin Cancer Res. 2020 Sep 15;26(18):4767-4776
pubmed: 32611648
J Clin Invest. 2019 Mar 1;129(3):1329-1344
pubmed: 30645202
Int J Cancer. 2020 Feb 15;146(4):1114-1124
pubmed: 31199520
Haematologica. 2020 Jan 9;:
pubmed: 31919076
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):23891-23893
pubmed: 31712441
Oncoimmunology. 2019 Jul 19;8(11):e1638207
pubmed: 31646086
Biochem Pharmacol. 2020 Jul;177:113986
pubmed: 32330494
Cell Cycle. 2012 Mar 1;11(5):1029-39
pubmed: 22333592
Cancer Treat Rev. 2018 Dec;71:1-7
pubmed: 30269007
Front Oncol. 2017 Sep 08;7:195
pubmed: 28944214
Leukemia. 2020 Aug;34(8):2150-2162
pubmed: 32060401
Oncogene. 2012 Feb 16;31(7):929-38
pubmed: 21785466
Oncotarget. 2016 Nov 1;7(44):71660-71672
pubmed: 27690219
Cancer Biol Ther. 2014 Apr;15(4):380-8
pubmed: 24365782
Oncogene. 2008 May 15;27(22):3081-90
pubmed: 18071311
Carcinogenesis. 2010 Jun;31(6):984-93
pubmed: 20142415
Clin Cancer Res. 2020 Jul 1;26(13):3431-3442
pubmed: 32209571
Cancers (Basel). 2019 Oct 10;11(10):
pubmed: 31636245
J Hematol Oncol. 2018 Aug 1;11(1):99
pubmed: 30068368
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
Clin Cancer Res. 2020 Apr 1;26(7):1667-1677
pubmed: 31806643
Clin Cancer Res. 2010 Feb 15;16(4):1094-9
pubmed: 20145169
Cancer Gene Ther. 2011 Oct;18(10):734-43
pubmed: 21836633
Cancer Res. 2019 Jul 15;79(14):3762-3775
pubmed: 31123088
Cancers (Basel). 2020 Jan 28;12(2):
pubmed: 32012873
J Clin Oncol. 2019 Oct 10;37(29):2643-2650
pubmed: 31398082
Sci Rep. 2018 Jan 17;8(1):948
pubmed: 29343688
Exp Cell Res. 2020 Jan 15;386(2):111720
pubmed: 31738907
Target Oncol. 2020 Feb;15(1):75-84
pubmed: 32034630
J Clin Invest. 2011 Apr;121(4):1283-97
pubmed: 21383502
Clin Cancer Res. 2008 Oct 15;14(20):6505-14
pubmed: 18927290
Nat Med. 2000 Oct;6(10):1134-9
pubmed: 11017145
Radiother Oncol. 2017 Feb;122(2):260-266
pubmed: 27939202
Haematologica. 2014 Apr;99(4):688-96
pubmed: 24179152
Cancer Cell. 2019 Jun 10;35(6):851-867.e7
pubmed: 31185210
Clin Cancer Res. 2019 Apr 1;25(7):2290-2304
pubmed: 30538111
Cancer Res. 2008 Oct 1;68(19):7923-31
pubmed: 18829549
Cell Mol Life Sci. 2013 Nov;70(21):4009-21
pubmed: 23508805
Front Oncol. 2019 Jul 12;9:564
pubmed: 31355131
Cancer Res. 2006 Jan 15;66(2):989-98
pubmed: 16424034
Hum Gene Ther. 2010 Sep;21(9):1067-76
pubmed: 20406097
J Exp Clin Cancer Res. 2018 Jun 28;37(1):129
pubmed: 29954437
Adv Exp Med Biol. 2017;1036:157-172
pubmed: 29275471
Cell Cycle. 2014;13(4):652-65
pubmed: 24345738
Biochem Pharmacol. 2019 Jun;164:273-282
pubmed: 31014753
Elife. 2020 Jul 06;9:
pubmed: 32628111
Oncoimmunology. 2018 Jul 23;7(10):e1488359
pubmed: 30288354
Cancer Lett. 2015 Jan 28;356(2 Pt B):656-68
pubmed: 25458954
Br J Haematol. 2020 Apr 21;:
pubmed: 32314355
Mol Oncol. 2015 Jan;9(1):78-92
pubmed: 25139258
Cancer Res. 2013 Jan 15;73(2):776-84
pubmed: 23135916
Cancers (Basel). 2019 Oct 25;11(11):
pubmed: 31717700
Cancer Res. 2018 Jun 1;78(11):3054-3066
pubmed: 29735549
Oncotarget. 2016 Jan 12;7(2):1380-94
pubmed: 26595527
Int J Cancer. 1998 Feb 9;75(4):649-53
pubmed: 9466670
Cancers (Basel). 2019 Nov 07;11(11):
pubmed: 31703356
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Neoplasia. 2018 May;20(5):478-488
pubmed: 29605721
Gastric Cancer. 2020 Jan;23(1):39-51
pubmed: 31197522
Cancer Biol Ther. 2010 Apr 1;9(7):523-5
pubmed: 20150761
Oncogene. 2018 Jul;37(27):3657-3671
pubmed: 29606701
Clin Cancer Res. 2019 Jun 1;25(11):3430-3442
pubmed: 30755439
J Toxicol Environ Health B Crit Rev. 2016;19(5-6):231-249
pubmed: 27705543
Oncotarget. 2015 Jul 20;6(20):17873-90
pubmed: 26160835
Oncotarget. 2016 Jan 12;7(2):1500-15
pubmed: 26625205
Mol Cancer. 2013 Sep 11;12(1):103
pubmed: 24020520
Cell Cycle. 2019 Apr;18(8):834-847
pubmed: 30943845
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Lancet. 2005 Jul 30-Aug 5;366(9483):397-408
pubmed: 16054941
Cell Res. 2015 Jan;25(1):9-23
pubmed: 25403473
Cell Death Dis. 2017 Dec 13;8(12):3206
pubmed: 29238045

Auteurs

Carmelina Antonella Iannuzzi (CA)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy.

Paola Indovina (P)

Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), I-80131 Naples, Italy.

Iris Maria Forte (IM)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy.
ORCID: 0000-0001-9490-5844

Sarah Di Somma (S)

Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", I-80131 Naples, Italy.

Anna Maria Malfitano (AM)

Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", I-80131 Naples, Italy.
ORCID: 0000-0002-6193-2835

Martina Bruno (M)

Department of Medical Biotechnologies, University of Siena, I-53100 Siena, Italy.

Giuseppe Portella (G)

Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", I-80131 Naples, Italy.

Francesca Pentimalli (F)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy.
ORCID: 0000-0003-4740-6801

Antonio Giordano (A)

Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Department of Medical Biotechnologies, University of Siena, I-53100 Siena, Italy.
ORCID: 0000-0002-5959-016X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ADN › Adenoviridae › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du silicium › Silice › Acide silicique › Silicates › Amiante › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs de la plèvre › Mésothéliome malin › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Thérapeutique › Biothérapie › Thérapie virale de cancers › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Virus › Virus oncolytiques › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Métabolisme › Phosphorylation › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Pharmacological Inhibition of WEE1 Potentiates...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Pharmacological Inhibition of WEE1 Potentiates...